These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 33603214)

  • 1. Ensuring continued progress for development of COVID-19 therapeutics in children.
    Noel GJ; DeBiasi RL; Crandall W; Connor EM
    Pediatr Res; 2021 Dec; 90(6):1112-1114. PubMed ID: 33603214
    [No Abstract]   [Full Text] [Related]  

  • 2. Lack of Effectiveness of Repurposed Drugs for COVID-19 Treatment.
    Martinez MA
    Front Immunol; 2021; 12():635371. PubMed ID: 33777024
    [No Abstract]   [Full Text] [Related]  

  • 3. Alopecia areata in a patient with SARS-Cov-2 infection.
    Sgubbi P; Savoia F; Calderoni O; Longo R; Stinchi C; Tabanelli M
    Dermatol Ther; 2020 Nov; 33(6):e14295. PubMed ID: 32909635
    [No Abstract]   [Full Text] [Related]  

  • 4. Cutaneous lesions and COVID-19: Cystic painful lesion in a case with positive SARS-CoV-2.
    Goudarzi S; Dehghani Firouzabadi F; Dehghani Firouzabadi M; Rezaei N
    Dermatol Ther; 2020 Nov; 33(6):e14266. PubMed ID: 32882081
    [No Abstract]   [Full Text] [Related]  

  • 5. Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19.
    Majumder J; Minko T
    AAPS J; 2021 Jan; 23(1):14. PubMed ID: 33400058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The challenges and opportunities of traditional Chinese medicines against COVID-19: a way out from a network perspective.
    Zuo HL; Lin YC; Huang HY; Wang X; Tang Y; Hu YJ; Kong XJ; Chen QJ; Zhang YZ; Hong HC; Li J; Hu SY; Huang HD
    Acta Pharmacol Sin; 2021 Jun; 42(6):845-847. PubMed ID: 33850275
    [No Abstract]   [Full Text] [Related]  

  • 7. COVID-19 Updates: Monoclonal Antibodies for COVID-19.
    Med Lett Drugs Ther; 2022 Jan; 64(1642):16. PubMed ID: 35139286
    [No Abstract]   [Full Text] [Related]  

  • 8. Repositioning chloroquine as antiviral prophylaxis against COVID-19: potential and challenges.
    Chang R; Sun WZ
    Drug Discov Today; 2020 Oct; 25(10):1786-1792. PubMed ID: 32629169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin-Converting-Enzyme 2 and Renin-Angiotensin System Inhibitors in COVID-19: An Update.
    Shukla AK; Banerjee M
    High Blood Press Cardiovasc Prev; 2021 Mar; 28(2):129-139. PubMed ID: 33635533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An EUA for bamlanivimab and etesevimab for COVID-19.
    Med Lett Drugs Ther; 2021 Apr; 63(1621):49-50. PubMed ID: 33830966
    [No Abstract]   [Full Text] [Related]  

  • 11. Coronavirus disease 2019 and epidermolysis bullosa: Report of three cases.
    Abdollahimajd F; Youssefian L; Pourani MR; Vahidnezhad H; Uitto J
    Dermatol Ther; 2020 Nov; 33(6):e14194. PubMed ID: 32794270
    [No Abstract]   [Full Text] [Related]  

  • 12. Regdanvimab: First Approval.
    Syed YY
    Drugs; 2021 Dec; 81(18):2133-2137. PubMed ID: 34724174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isolated maculopapular eruption localized to head and neck: A cutaneous sign of COVID-19 infection.
    Farabi B; Atak MF
    Dermatol Ther; 2020 Nov; 33(6):e14468. PubMed ID: 33112023
    [No Abstract]   [Full Text] [Related]  

  • 14. CD147 inhibitors as a treatment for melanoma: Promising agents against SARS-CoV-2 infection.
    Pourani MR; Nekooghadam SM; Youssefian L; Vahidnezhad H; Abdollahimajd F
    Dermatol Ther; 2020 Nov; 33(6):e14449. PubMed ID: 33098610
    [No Abstract]   [Full Text] [Related]  

  • 15. An EUA for sotrovimab for treatment of COVID-19.
    Med Lett Drugs Ther; 2021 Jun; 63(1627):97-xx98. PubMed ID: 34181630
    [No Abstract]   [Full Text] [Related]  

  • 16. Safety and effectiveness concerns of lopinavir/ritonavir in COVID-19 affected patients: a retrospective series.
    Lepage MA; Rozza N; Kremer R; Grunbaum A
    Clin Toxicol (Phila); 2021 Jul; 59(7):644-647. PubMed ID: 33641562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical efficacy and safety profile of hydroxychloroquine and azithromycin against COVID-19.
    Gautret P; Lagier JC; Honoré S; Hoang VT; Raoult D
    Int J Antimicrob Agents; 2021 Jan; 57(1):106242. PubMed ID: 33408033
    [No Abstract]   [Full Text] [Related]  

  • 18. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial revisited.
    Gautret P; Lagier JC; Honoré S; Hoang VT; Colson P; Raoult D
    Int J Antimicrob Agents; 2021 Jan; 57(1):106243. PubMed ID: 33408014
    [No Abstract]   [Full Text] [Related]  

  • 19. Coronavirus disease 2019 in a psoriatic patient with concomitant chronic obstructive pulmonary disease under treatment with risankizumab.
    Kiss N; Lőrincz K; Medvecz M; Fésűs L; Csuha P; Hermányi Z; Wikonkál NM
    Dermatol Ther; 2020 Nov; 33(6):e14186. PubMed ID: 32794375
    [No Abstract]   [Full Text] [Related]  

  • 20. Antibodies to watch in 2021.
    Kaplon H; Reichert JM
    MAbs; 2021; 13(1):1860476. PubMed ID: 33459118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.